Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT01419158
Last Updated: 2012-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3457 participants
OBSERVATIONAL
2008-01-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
NCT05297812
The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency
NCT00532805
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
NCT00001462
Alpha1-antitrypsin Deficiency Registry
NCT00005292
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
NCT00700934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All races and ethnicities will be considered for this study.
* Post-bronchodilator values for pulmonary function tests on the day of enrollment with an FEV1 \< 80% of predicted and FEV1/FVC \< 70% (at least GOLD stage II).
* Subjects who have been tested for Alpha-1 in the past but do not know their genotype or phenotype may be included in this study.
Exclusion Criteria
* Subjects whose ordering physician has specifically requested that his patients not be considered for enrollment.
* Patients who have been tested for Alpha-1 in the past and know their genotype or phenotype.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alpha-1 Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert A Sandhaus, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Jewish Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles
Los Angeles, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
University of Florida (Gainesville)
Gainesville, Florida, United States
University of Florida (Jacksonville)
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Miami VA Medical Center
Miami, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Emory Crawford Long Hospital
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Atlanta VA Medical Center
Decatur, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
St. Luke's-Roosevelt Hospital Center
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Texas Health Science Center at Tyler
Tyler, Texas, United States
San Juan City Hospital
Centro Medico Metropolitano, San Juan, Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PFT-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.